NCT00438854View on ClinicalTrials.gov

Dasatinib in Relapsed Chronic Lymphocytic Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

October 31, 2010

Study Completion Date

March 31, 2013

Conditions
Chronic Lymphocytic Leukemia
Interventions
DRUG

Dasatinib

Taken orally once daily. Participants may continue on study treatment as long as there is no disease progression or serious side effects.

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Massachusetts General Hospital

OTHER